TYRATyra Biosciences, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$132M
- 28% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$26M | −$59M | −$80M | −$104M | −$133M | 27% |
| Net income | −$26M | −$55M | −$69M | −$86M | −$120M | 39% |
| Operating cash flow | −$24M | −$50M | −$50M | −$70M | −$95M | 36% |
| Capex | $661K | $559K | $770K | $664K | $141K | 79% |
| Stock-based comp | $3M | $11M | $14M | $23M | $28M | 23% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $20K · 1
- Open-market sells, 12 mo
- $0 · 0
- Net
- $20K
Pay vs performance
No pay-versus-performance disclosure yet.